Abstract
Purpose Glucocorticoids are widely used to treat acute respiratory distress syndrome (ARDS) despite its use is highly controversial based on randomized controlled trials and meta-analyses. As type I interferons (IFNs) are our first line of defense against severe viral respiratory infections, we explored whether glucocorticoids interfere with IFN signaling and whether their use associates to outcome of IFN beta treatment of ARDS.
Methods We performed a propensity-matched post-hoc-analysis using data from the recent randomized INTEREST-trial comparing IFN beta-1a to placebo in ARDS patients. Based on the results of these analyses we utilized human lung tissue and human pulmonary endothelial cell cultures to investigate the effect of hydrocortisone on IFN nuclear signaling and the protein transcription of CD73, a molecule responsible for vascular integrity.
Results We found that hydrocortisone reduces the production, and prevents the nuclear translocation of IRF9, that is required for IFN beta-dependent signaling of multiple IFN-induced genes. In addition, hydrocortisone inhibits IFN beta-dependent upregulation of CD73 in human lung tissue. Additionally, we found that use of glucocorticoids with IFN beta-1a was independently associated with increased mortality (OR 5.4, 95% CI 2.1–13.9, P< 0.001) in the INTEREST-trial.
Conclusions Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung. This provides the mechanistic basis for the harmful association of glucocorticoids in IFN beta treated patients in the INTEREST-trial. Most importantly, it strongly speaks against the use of glucocorticoids in viral-induced ARDS such as in the current corona virus pandemia.
Take home message Glucocorticoids inhibit type I interferon beta signaling and the upregulation of CD73 that is a key molecule preventing vascular leakage and harmful leukocyte infiltration into the lungs. This work provides the mechanistic basis for the need to avoid glucocorticoids in viral-induced ARDS, in which endogenous interferon is needed to combat the infection and its consequences.
Competing Interest Statement
JJ, MK, JM and MJ are employees and shareholders of Faron Pharmaceuticals. MH and SJ own stocks of Faron Pharmaceuticals and SJ has a patent (US 7534423).
Clinical Trial
The original data are from INTEREST trial: ClincalTrials.gov Identifier NCT02622724
Funding Statement
Academy of Finland, Faron Pharmaceuticals Ltd, European Union Seventh Framework Program (grant agreement No. 305853)
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data and the novel reagent (anti-CD73 antibody) will be made available to others on reasonable requests to the corresponding author
Abbreviations
- (APACHE) II
- Acute Physiology and Chronic Health Evaluation
- (IFN(
- interferon
- (SOFA)
- Sequential Organ Failure Assessment
